Diabetic foot osteomyelitis

Bone markers and treatment outcomes

Humaa A. Nyazee, Kristina M. Finney, Molly Sarikonda, Dwight A. Towler, Jeffrey E. Johnson, Hilary M. Babcock

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims: Novel bone turnover markers could help with the diagnosis and monitoring of osteomyelitis patients. We compared levels of two bone turnover markers, serum amino-terminal telopeptides (NTx) and bone alkaline phosphatase (BAP), in diabetic patients with and without osteomyelitis. Methods: Matched case-control study was conducted with diabetic patients with and without osteomyelitis. Cases not undergoing immediate amputation were followed with repeat measurements after osteomyelitis treatment and for outcome determination. Results: Analysis included 54 subjects, 27 cases and 27 controls. Median BAP levels were similar between cases and controls at enrollment (p= .55) as were median NTx levels (p= .43). Cases with follow-up data (n=18) had similar bone marker levels at enrollment and 6 weeks. No significant differences in BAP or NTx levels at enrollment or follow-up were seen between cases with poor versus favorable outcomes. Conclusions: No differences in NTx or BAP levels were seen between cases and controls. Cases with follow-up data had similar levels at enrollment and 6 weeks. Lack of difference may be due to small sample size, small areas of bone involved in foot osteomyelitis, or limitations of these specific markers. More research is needed.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalDiabetes Research and Clinical Practice
Volume97
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Foot Bones
Diabetic Foot
Osteomyelitis
Bone and Bones
Alkaline Phosphatase
Bone Remodeling
Physiologic Monitoring
Amputation
Sample Size
Case-Control Studies
Foot
Biomarkers
Research

Keywords

  • Bone markers
  • Diabetic foot ulcers
  • Osteomyelitis
  • Treatment outcomes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology

Cite this

Diabetic foot osteomyelitis : Bone markers and treatment outcomes. / Nyazee, Humaa A.; Finney, Kristina M.; Sarikonda, Molly; Towler, Dwight A.; Johnson, Jeffrey E.; Babcock, Hilary M.

In: Diabetes Research and Clinical Practice, Vol. 97, No. 3, 01.09.2012, p. 411-417.

Research output: Contribution to journalArticle

Nyazee, Humaa A. ; Finney, Kristina M. ; Sarikonda, Molly ; Towler, Dwight A. ; Johnson, Jeffrey E. ; Babcock, Hilary M. / Diabetic foot osteomyelitis : Bone markers and treatment outcomes. In: Diabetes Research and Clinical Practice. 2012 ; Vol. 97, No. 3. pp. 411-417.
@article{652dab030a714808a5fd9d617bfdf405,
title = "Diabetic foot osteomyelitis: Bone markers and treatment outcomes",
abstract = "Aims: Novel bone turnover markers could help with the diagnosis and monitoring of osteomyelitis patients. We compared levels of two bone turnover markers, serum amino-terminal telopeptides (NTx) and bone alkaline phosphatase (BAP), in diabetic patients with and without osteomyelitis. Methods: Matched case-control study was conducted with diabetic patients with and without osteomyelitis. Cases not undergoing immediate amputation were followed with repeat measurements after osteomyelitis treatment and for outcome determination. Results: Analysis included 54 subjects, 27 cases and 27 controls. Median BAP levels were similar between cases and controls at enrollment (p= .55) as were median NTx levels (p= .43). Cases with follow-up data (n=18) had similar bone marker levels at enrollment and 6 weeks. No significant differences in BAP or NTx levels at enrollment or follow-up were seen between cases with poor versus favorable outcomes. Conclusions: No differences in NTx or BAP levels were seen between cases and controls. Cases with follow-up data had similar levels at enrollment and 6 weeks. Lack of difference may be due to small sample size, small areas of bone involved in foot osteomyelitis, or limitations of these specific markers. More research is needed.",
keywords = "Bone markers, Diabetic foot ulcers, Osteomyelitis, Treatment outcomes",
author = "Nyazee, {Humaa A.} and Finney, {Kristina M.} and Molly Sarikonda and Towler, {Dwight A.} and Johnson, {Jeffrey E.} and Babcock, {Hilary M.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.diabres.2012.04.002",
language = "English (US)",
volume = "97",
pages = "411--417",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Diabetic foot osteomyelitis

T2 - Bone markers and treatment outcomes

AU - Nyazee, Humaa A.

AU - Finney, Kristina M.

AU - Sarikonda, Molly

AU - Towler, Dwight A.

AU - Johnson, Jeffrey E.

AU - Babcock, Hilary M.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Aims: Novel bone turnover markers could help with the diagnosis and monitoring of osteomyelitis patients. We compared levels of two bone turnover markers, serum amino-terminal telopeptides (NTx) and bone alkaline phosphatase (BAP), in diabetic patients with and without osteomyelitis. Methods: Matched case-control study was conducted with diabetic patients with and without osteomyelitis. Cases not undergoing immediate amputation were followed with repeat measurements after osteomyelitis treatment and for outcome determination. Results: Analysis included 54 subjects, 27 cases and 27 controls. Median BAP levels were similar between cases and controls at enrollment (p= .55) as were median NTx levels (p= .43). Cases with follow-up data (n=18) had similar bone marker levels at enrollment and 6 weeks. No significant differences in BAP or NTx levels at enrollment or follow-up were seen between cases with poor versus favorable outcomes. Conclusions: No differences in NTx or BAP levels were seen between cases and controls. Cases with follow-up data had similar levels at enrollment and 6 weeks. Lack of difference may be due to small sample size, small areas of bone involved in foot osteomyelitis, or limitations of these specific markers. More research is needed.

AB - Aims: Novel bone turnover markers could help with the diagnosis and monitoring of osteomyelitis patients. We compared levels of two bone turnover markers, serum amino-terminal telopeptides (NTx) and bone alkaline phosphatase (BAP), in diabetic patients with and without osteomyelitis. Methods: Matched case-control study was conducted with diabetic patients with and without osteomyelitis. Cases not undergoing immediate amputation were followed with repeat measurements after osteomyelitis treatment and for outcome determination. Results: Analysis included 54 subjects, 27 cases and 27 controls. Median BAP levels were similar between cases and controls at enrollment (p= .55) as were median NTx levels (p= .43). Cases with follow-up data (n=18) had similar bone marker levels at enrollment and 6 weeks. No significant differences in BAP or NTx levels at enrollment or follow-up were seen between cases with poor versus favorable outcomes. Conclusions: No differences in NTx or BAP levels were seen between cases and controls. Cases with follow-up data had similar levels at enrollment and 6 weeks. Lack of difference may be due to small sample size, small areas of bone involved in foot osteomyelitis, or limitations of these specific markers. More research is needed.

KW - Bone markers

KW - Diabetic foot ulcers

KW - Osteomyelitis

KW - Treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=84866564833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866564833&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2012.04.002

DO - 10.1016/j.diabres.2012.04.002

M3 - Article

VL - 97

SP - 411

EP - 417

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -